{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:09:58Z","timestamp":1791007798640,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,5,25]],"date-time":"2004-05-25T00:00:00Z","timestamp":1085443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Methotrexate\u2010based and alkylator\u2010based chemotherapy regimens are associated with renal and bone marrow toxicities, which limit their use in patients with central nervous system (CNS) lymphomas. The authors report their experience with an immunochemotherapy regimen consisting of rituximab and temozolomide in patients with primary or metastatic CNS lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non\u2010Hodgkin lymphoma developed recurrent lymphoma in the brain only. Patients were scheduled to receive 4 cycles of induction rituximab on Day 1 and temozolomide on Days 1\u20135 of a 28\u2010day cycle. Thereafter, their treatment included a total of up to 8 maintenance cycles of temozolomide alone on Days 1\u20135 of a 28\u2010day cycle. A gadolinium\u2010enhanced magnetic resonance image of the head was obtained after every two cycles of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>All patients received rituximab without toxicity. Of the 4 patients who received induction temozolomide at doses &gt; 150 mg\/m<jats:sup>2<\/jats:sup> daily on Days 1\u20135, 2 experienced Grade 2 leukopenia and thrombocytopenia. Five patients achieved a radiographic complete response, and two patients had partial responses after induction treatment. The median response duration was 6 months (range 3\u201312+ months), and the median survival was 8 months (range 3+\u201312+ months).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Although median survival was short, immunochemotherapy with rituximab and temozolomide was well tolerated and exhibited efficacy in this elderly and heavily pretreated cohort. The data obtained in the current study suggest that the optimal induction dose combination consists of rituximab 375 mg\/m<jats:sup>2<\/jats:sup> on Day 1 and temozolomide 150 mg\/m<jats:sup>2<\/jats:sup> daily on Days 1\u20135. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20339","type":"journal-article","created":{"date-parts":[[2004,5,26]],"date-time":"2004-05-26T11:13:09Z","timestamp":1085569989000},"page":"139-145","source":"Crossref","is-referenced-by-count":99,"title":["Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas"],"prefix":"10.1002","volume":"101","author":[{"given":"Eric T.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Tishler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian K.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,5,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.635"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1707"},{"key":"e_1_2_5_4_2","first-page":"165a","article-title":"Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma","volume":"19","author":"Ciordia R","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.17.1408"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.9.1721"},{"key":"e_1_2_5_8_2","first-page":"166a","article-title":"Activity of rituximab in primary central nervous system lymphoma (PCNSL)","volume":"19","author":"Raizer JJ","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1636"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050842"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30156"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007026504843"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.7.575"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1019682400415"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.10.1573"},{"key":"e_1_2_5_16_2","first-page":"347","article-title":"Primary central nervous system lymphoma: response to temozolomide therapy","volume":"5","author":"Angelov L","year":"2003","journal-title":"Neuro\u2010oncol."},{"key":"e_1_2_5_17_2","first-page":"354","article-title":"Phase II treatment of adults with newly diagnosed, progressive, or recurrent primary central nervous system lymphoma with Temodar","volume":"5","author":"Quinn J","year":"2003","journal-title":"Neuro\u2010oncol."},{"key":"e_1_2_5_18_2","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down\u2010regulation of Bcl\u20102 and sensitization of B\u2010cell non\u2010Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas S","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_19_2","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B\u2010non\u2010Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down\u2010regulation of Bcl\u20102 and sensitization to cytotoxic drugs","volume":"61","author":"Alas S","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_5_22_2","first-page":"604a","article-title":"Final results of a Phase II study to evaluate the efficacy and safety of treatment and retreatment with rituximab in relapsed follicular or low\u2010grade NHL","volume":"98","author":"Lopez A","year":"2001","journal-title":"Blood."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.027"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20339","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:53:03Z","timestamp":1760266383000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1002\/cncr.20339"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20339","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,25]]}}}